Heart Disease & Cardiology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This large Phase 3 clinical trial is testing a new oral medication called enlicitide decanoate in people who are at high risk for heart attacks and strokes. If successful, this treatment could provide an easier way to lower bad cholesterol and reduce serious heart problems. The study includes over 14,000 participants across many countries and is currently active but not recruiting.

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

This Phase 3 study is evaluating AZD0780, another oral PCSK9 inhibitor, in people with existing heart disease or those at high risk for their first cardiovascular event. It aims to find out if this medicine can reduce major heart problems like heart attacks and strokes. The trial is recruiting participants worldwide and will analyze results after a set number of events occur.

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

This Phase 4 trial is investigating whether giving adenosine before emergency heart procedures can improve outcomes for patients having a specific type of heart attack called STEMI. The goal is to see if this pre-treatment can reduce complications and improve blood flow during the procedure. The study is recruiting over 1,100 patients in Pakistan.

Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics

This completed Phase 4 study looked at how a treatment called incretin therapy affects heart fat and health outcomes after bypass surgery in people with coronary artery disease, comparing those with and without diabetes. The results may help doctors better understand how to reduce heart risks and improve survival in patients with diabetes after surgery. The study took place in Italy with 150 participants.

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

This Phase 2 trial is testing montelukast, an oral medication, to see if it can lower inflammation and reduce heart damage in patients who recently had a heart attack. If effective, this treatment could support better recovery after a heart attack. The study is currently recruiting 80 participants at Mansoura University.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.